Abstract:The recent Trial to Assess Chelation Therapy (TACT) study, enrolling subjects who had previously experienced a myocardial infarction, has provided strong evidence that intravenous chelation therapy can markedly reduce risk for mortality and vascular events in diabetics, whereas no discernible benefit was observed in non-diabetics. It has plausibly been suggested that this reflects a role for transition metal ions--iron or copper--in the genesis of advanced glycation end products, key mediators of diabetic complications that can destabilize plaque. Since phlebotomy therapy fails to prevent vascular events in diabetics, we hypothesize that labile copper may be the chief culprit whose removal by chelation mediated the benefit observed in TACT. If so, strategies less time and labor intensive than chelation therapy might provide comparable benefit. A number of recent studies report that the copper-specific orally-active chelator trientine can reduce risk for range of diabetic complications in rodents; a clinical trial with this agent demonstrated some decrease in left ventricular mass in diabetics with ventricular hypertrophy. However, until this agent becomes less expensive, supplementation with high-dose zinc may represent a more feasible alternative. Zinc opposes the absorption and redox activity of copper via induction of the antioxidant protein metallothionein, which binds copper tightly. A great many studies demonstrate that increased expression of metallothionein decreases risk for tissue damage in diabetic rodents, and in some of these studies metallothionein expression was boosted by supplemental zinc. Zinc supplementation also modestly improves glycemic control in type 2 diabetics, and might reduce risk for diabetes by protecting pancreatic beta cells from oxidative stress. A long term study assessing the impact of supplementing diabetics with high-dose zinc, assessing risk for mortality, vascular events, and diabetic complications, may be warranted. Histidine, which readily forms complexes with copper that possess superoxide dismutase activity, also has potential for alleviating the contribution of loosely bound copper to AGE formation; moreover, in a recent clinical study, supplemental histidine improved insulin sensitivity and exerted anti-inflammatory and antioxidant effects in women with metabolic syndrome. Since ascorbate can reduce labile copper and thereby enhance its pathogenicity, the impact of high-dose ascorbate supplementation on cardiovascular risk in diabetics should receive further study.

Diving deep into chelation therapy for coronary artery disease: a review

Chelation therapy to prevent diabetes-associated cardiovascular events

Subsequent Cardiac and Stroke Events in Patients with Known Vascular Disease Treated with EDTA Chelation Therapy

The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies

Chelators in Iron and Copper Toxicity

Heavy metal toxicity: An update of chelating therapeutic strategies

Citric Acid and EDTA as chelating agents in phytoremediation of heavy metal in polluted soil: a review

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Metal Chelation as a Potential Therapy for Alzheimer's Disease

Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?

The protection conferred by chelation therapy in post-MI diabetics might be replicated by high-dose zinc supplementation

The Role of Chelation in the Treatment of Other Metal Poisonings

Synthetic and natural iron chelators: therapeutic potential and clinical use

Exogeneous Metal Ions As Therapeutic Agents in Cardiovascular Disease and Their Delivery Strategies.

Vitamin K and Calcium Chelation in Vascular Health

Understanding Alzheimer's Disease and its Metal Chelation Therapeutics: A Narrative Review

EDTA Chelation Therapy for the Treatment of Neurotoxicity

The impact of chelating compounds on Cu2+, Fe2+/3+, and Zn2+ ions in Alzheimer's disease treatment

Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

Design of iron chelators with therapeutic application